Breaking News Instant updates and real-time market news.

LIFE

aTyr Pharma

, OCX

OncoCyte

$6.30

-1.05 (-14.29%)

04:55
05/24/17
05/24
04:55
05/24/17
04:55

American Thoracic Society to hold a conference

ATS International Conference 2017 is being held in Washington, D.C. on May 19-24.

LIFE

aTyr Pharma

OCX

OncoCyte

$6.30

-1.05 (-14.29%)

TEVA

Teva

$28.76

-0.68 (-2.31%)

BLPH

Bellerophon

$1.43

-0.07 (-4.67%)

BDX

Becton Dickinson

$186.62

1.85 (1.00%)

PFE

Pfizer

$32.14

0.02 (0.06%)

WTKWY

Wolters Kluwer

$44.05

-0.58 (-1.30%)

DDD

3D Systems

$22.37

-0.03 (-0.13%)

AZN

AstraZeneca

$34.08

0.13 (0.38%)

MNK

Mallinckrodt

$39.86

-0.18 (-0.45%)

GSK

GlaxoSmithKline

$42.96

-0.34 (-0.79%)

FGEN

FibroGen

$26.90

0.3 (1.13%)

NVS

Novartis

$81.06

-0.23 (-0.28%)

PRXL

Parexel

$79.64

0.33 (0.42%)

NSPR

InspireMD

$0.57

0.0085 (1.53%)

MYL

Mylan

$39.59

0.95 (2.46%)

ABBV

AbbVie

$65.84

0.4 (0.61%)

VRTX

Vertex

$116.59

-2.35 (-1.98%)

VCYT

Veracyte

$8.25

-0.03 (-0.36%)

RMD

ResMed

$69.60

0.09 (0.13%)

MASI

Masimo

$85.83

-0.1 (-0.12%)

REGN

Regeneron

$461.37

0.38 (0.08%)

INSM

Insmed

$17.24

-0.13 (-0.75%)

BAYRY

Bayer

$131.91

0.62 (0.47%)

  • 24

    May

  • 25

    May

  • 30

    May

  • 31

    May

  • 01

    Jun

  • 02

    Jun

  • 06

    Jun

  • 07

    Jun

  • 08

    Jun

  • 09

    Jun

  • 09

    Jun

  • 13

    Jun

  • 20

    Jun

  • 26

    Jun

  • 27

    Aug

  • 30

    Aug

  • 03

    Sep

  • 09

    Oct

LIFE aTyr Pharma

12/13/16
JPMS
12/13/16
DOWNGRADE
JPMS
Neutral
aTyr Pharma downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Cory Kasimov downgraded aTyr Pharma to Neutral.
12/13/16
JPMS
12/13/16
DOWNGRADE
JPMS
Neutral
JPMorgan downgrades aTyr Pharma on 'mixed' data
JPMorgan analyst Cory Kasimov downgraded aTyr Pharma to Neutral from Overweight saying the company's Phase 1/2 data for Resolaris from three different studies is a "mixed bag." The data announced today still don't fully define proof-of concept, Kasimov tells investors in a research note. He thinks the company will need time to establish a clear path forward. Kasimov has no target for the shares. aTyr shares are down 80c to $2.85 in afternoon trading.
OCX OncoCyte
$6.30

-1.05 (-14.29%)

02/23/17
CHDN
02/23/17
INITIATION
Target $6.5
CHDN
Buy
OncoCyte initiated with a Buy at Chardan
Chardan analyst Keay Nakae initiated OncoCyte with a Buy and a $6.50 price target.
03/07/17
JANY
03/07/17
UPGRADE
JANY
Neutral
Foundation Medicine upgraded to Neutral from Sell at Janney Capital
Janney Capital analyst Paul Knight upgraded Foundation Medicine (FMI) to Neutral from Sell, citing "easy" earnings comparisons in Q1 and low expectations. In his upgrade note, Knight added that if Foundation's recent rebound is due to a change in sector perception, then he views Veracyte (VCYT), CaredDx (CDNA), and Oncocyte (OCX) as having "more catalysts, more revenue visibility, and better value" and sees all three as undervaled.
05/23/17
BNCH
05/23/17
NO CHANGE
Target $12
BNCH
Speculative Buy
OncoCyte price target raised to $12 after 'strong' lung test data at Benchmark
Benchmark analyst Raymond Myers said OncoCyte reported "strong" validation study results for its lung cancer diagnostic test, noting that the 73% specificity reported was "meaningfully better" than the 50% specificity threshold he estimates is necessary to support commercial success for the test. The study reduces OncoCyte's risk profile and supports increasing his price target on the stock to $12 from $10, he tells investors. Myers keeps a Speculative Buy rating on OncoCyte shares.
02/23/17
02/23/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Monsanto (MON) initiated with a Sector Perform at RBC Capital. 2. FMC Corporation (FMC) initiated with an Outperform at RBC Capital. 3. OncoCyte (OCX) initiated with a Buy at Chardan. 4. Jazz Pharmaceuticals (JAZZ) initiated with a Buy at Evercore ISI. 5. Reata Pharmaceuticals (RETA) initiated with a Buy at Stifel. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
TEVA Teva
$28.76

-0.68 (-2.31%)

05/01/17
JEFF
05/01/17
NO CHANGE
Target $67
JEFF
Buy
Jefferies ups Neurocrine target on 'encouraging' doctor survey
Jefferies analyst Biren Amin raised his price target for Neurocrine Biosciences (NBIX) to $67 from $65 after his firm, for the second time, surveyed 50 U.S. doctors on the current and future Tardive Dyskinesia treatment landscape. The shares closed Friday down 19c to $53.40. The respondents estimate "significant uptake" of both Neurocrine's valbenazine and Teva's (TEVA) Austedo with a "clear preference" for valbenazine, Amin tells investors in a research note. The analyst now expects valbenazine to capture a larger share than Austedo in moderate-to-severe Tardive Dyskinesia. Amin keeps a Buy rating on Neurocrine shares.
05/11/17
WELS
05/11/17
NO CHANGE
WELS
Market Perform
Teva faces 'underappreciated risk' from major generic RFPs, says Wells Fargo
Wells Fargo analyst David Maris noted that Teva's generic drug price erosion came in at 7% in Q1, adding that Teva's management, which previously indicated that they expected price erosion in the U.S. to be 5%, "did not explain well" how the factors that negatively impacted prices were not fully anticipated. Also, there are currently two major generic Request for Proposals out for bid - one from Express Scripts (ESRX), Albertson's and Kroger (KR) and one from Walmart (WMT) and McKesson (MCK) - and the potential price reset from these is an "underappreciated risk" facing Teva, added Maris, who keeps a Market Perform rating on the stock.
04/25/17
WELS
04/25/17
NO CHANGE
WELS
Novartis results highlight tough pricing environment, says Wells Fargo
This morning's Q1 results from Novartis' (NVS) Sandoz division highlight the difficult U.S. generic price environment, Wells Fargo analyst David Maris tells investors in a research note. Sandoz experienced pricing erosion of 8% in the quarter, which represents the largest negative impact from pricing in recent quarters, Maris writes. He expects the negative U.S. pricing environment to impact including Mallinckrodt (MNK), Teva (TEVA), Mylan (MYL) and Perrigo (PRGO). Maris remains cautious on the pricing environment for generics.
05/02/17
LEHM
05/02/17
NO CHANGE
Target $70
LEHM
Overweight
Neurocrine price target raised to $70 from $60 at Barclays
Barclays analyst Geoff Meacham raised his price target for Neurocrine Biosciences (NBIX) to $70 and maintains an Overweight rating on the shares. Ingrezza pricing came in ahead of expectations at $50,000 per year net, Meacham tells investors in a research note. He believes the net cost of Ingrezza is favorably positioned relative to Teva's (TEVA) Austedo.
BLPH Bellerophon
$1.43

-0.07 (-4.67%)

01/20/17
HCWC
01/20/17
INITIATION
Target $5
HCWC
Buy
Bellerophon initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Andrew Fein initaited Bellerophon with a Buy and a $5 price target saying inhaled nitric oxide, or NO, therapy alone offers upside to current valuation. Fein believes Bellerophon's portable, userfriendly device, INOpulse, offers a competitive value proposition as adjuvant therapy for pulmonary arterial hypertension patients already on long-term oxygen support and conservatively models for a worldwide peak revenue of $238M for INOpulse by the year 2023.
04/17/17
LTCO
04/17/17
INITIATION
Target $4.5
LTCO
Buy
Bellerophon initiated with a Buy at Ladenburg
Ladenburg Thalmann analyst Christopher James started Bellerophon Therapeutics with a Buy rating and $4.50 price target. The analyst views the valuation as depressed and considers two Phase 2 readouts and an interim peek into the first Phase 3 study to be "major potential catalysts" for 2017.
BDX Becton Dickinson
$186.62

1.85 (1.00%)

05/23/17
MSCO
05/23/17
NO CHANGE
MSCO
Medtech Technology sector upgraded to Attractive from In-Line at Morgan Stanley
Morgan Stanley upgraded the Medtech Technology sector to Attractive saying structural fundamentals have improved and recent acceleration will likely continue, driving further multiple expansion.
04/24/17
EVER
04/24/17
UPGRADE
EVER
Outperform
Becton Dickinson upgraded to Outperform from In Line at Evercore ISI
04/24/17
04/24/17
UPGRADE
Target $200

Outperform
Update: Becton Dickinson upgraded to Outperform at Evercore ISI
As previously reported, Evercore ISI upgraded Becton Dickinson (BDX) to Outperform with a $200 price target following weakness related to the C.R. Bard (BCR) acquisition. Analyst Vijay Kumar believes the deal makes Becton Dickinson a powerhouse in hospital supplies segment and possibly puts them in better bargaining position. He notes management has a history of execution and and is comforted by his expectations double-digit earnings growth and a 1%+ dividend yield for Becton Dickinson.
04/25/17
LEER
04/25/17
NO CHANGE
Target $317
LEER
Market Perform
C.R. Bard price target raised to $317 from $246 at Leerink
Leerink analyst Richard Newitter raised his price target for C.R. Bard (BCR) to $317 from $246 following the announced acquisition price from Becton Dickinson (BDX). The analyst reiterates a Market Perform rating as he believes the deal price fully values C.R. Bard and sees limited risk of a competitive bid or barriers from the FTC.
PFE Pfizer
$32.14

0.02 (0.06%)

05/16/17
SBSH
05/16/17
DOWNGRADE
Target $31
SBSH
Sell
Pfizer downgraded to Sell from Neutral at Citi
Citi analyst Andrew Baum downgraded Pfizer (PFE) to Sell and cut his price target for the shares to $31 from $38. The biopharmaceutical giant closed yesterday up 11c to $33.12. The analyst says his concern over Pfizer's "rising risk to high price" Medicare Part D covered oncology drugs, namely Xtandi, Ibrance and Xalkori, has intensified. He also believes "major transaction risk" for Pfizer remains high. Bristol-Myers (BMY) and Allergan (AGN) are the most probable takeover targets for Pfizer, Baum tells investors in a research note. The analyst prefers owning Eli Lilly (LLY) and Bristol among the major U.S. Pharmaceuticals.
04/16/17
PIPR
04/16/17
DOWNGRADE
Target $124
PIPR
Neutral
Incyte downgraded to Neutral from Overweight at Piper Jaffray
Piper Jaffray analyst Joshua Schimmer downgraded Incyte (INCY) to Neutral and cut his price target for the shares to $124 from $140. The biopharmaceutical company closed Thursday up $2.57 to $140.84. Incyte and Eli Lilly (LLY) announced Friday that the FDA issued a complete response letter for baricitinib, indicating a need to determine appropriate doses. This setback could take years and lead to approval of only the lower dose, leaving potentially little differentiation from Pfizer's (PFE) rheumatoid arthritis treatment Xeljanz," Schimmer tells investors in a research note. The analyst prefers to wait for a "cleaner entry point" into the shares.
05/16/17
05/16/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Pfizer (PFE) downgraded to Sell from Neutral at Citi with analyst Andrew Baum saying his concern over Pfizer's "rising risk to high price" Medicare Part D covered oncology drugs, namely Xtandi, Ibrance and Xalkori, has intensified. He also believes "major transaction risk" for Pfizer remains high. 2. MercadoLibre (MELI) downgraded to Neutral from Overweight at JPMorgan with analyst Andre Baggio citing valuation with the stock up 131% year-over-year. 3. Eli Lilly (LLY) downgraded to Buy from Conviction Buy at Goldman Sachs with analyst Jami Rubin citing strong year-to-date performance. The analyst maintained a Buy rating and $92 price target citing favorable long-term fundamentals with significant margin expansion. 4. Valero (VLO) downgraded to Neutral from Buy at Goldman Sachs with analyst Neil Mehta citing a more balanced risk/reward following the stock's outperformance. 5. NantKwest (NK) downgraded to Sell from Neutral at Citi with analyst Joel Beatty saying the company has a history of "significantly missing" its clinical trial timelines, and this is unlikely to change over the near-term. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
05/03/17
BMOC
05/03/17
DOWNGRADE
BMOC
Underperform
Bristol-Myers downgraded on lower takeover odds at BMO Capital
As noted earlier, BMO Capital downgraded Bristol-Myers (BMY) to Underperform from Market Perform. Analyst Alex Arfaei downgraded the stock partly based on comments by Pfizer's (PFE) CEO yesterday which indicated that his company wouldn't look to buy Bristol-Myers in the near-term. Arfaei says that the chances of Bristol-Myers being acquired are "relatively low," as he thinks that the risk posed by the company's immunotherapy franchise will increase this year, while U.S. tax reform initiatives create uncertainty about large deals. Target $47.
WTKWY Wolters Kluwer
$44.05

-0.58 (-1.30%)

03/10/17
GSCO
03/10/17
UPGRADE
GSCO
Neutral
Wolters Kluwer upgraded to Neutral from Sell at Goldman
DDD 3D Systems
$22.37

-0.03 (-0.13%)

01/10/17
PIPR
01/10/17
NO CHANGE
PIPR
Piper more positive on Stratasys, sees 'meaningful downside' for 3D
Piper Jaffray analyst Troy Jensen says his firm's 3D printing industry survey for Q4 indicated a sequential uptick in system demand, but not for all companies. The survey indicated Stratasys (SSYS) resellers saw a "meaningful" quarter-over-quarter improvement, while most 3D Systems (DDD) resellers continue to underperform, Jensen tells investors in a research note. Shares of 3D, are rallying on takeover speculation, do not reflect the underlying fundamentals, the analyst contends. He continues to see "meaningful downside" in the shares. Jensen is "incrementally more positive" on Stratasys following the survey, but reiterates a Neutral rating on the name.
05/04/17
PIPR
05/04/17
NO CHANGE
Target $11
PIPR
Underweight
3D Systems quarter 'less bad,' says Piper Jaffray
Piper Jaffray analyst Troy Jensen views 3D Systems' March quarter results as "less bad" versus recent quarters. The analyst, however, still has concerns regarding sustainable system growth and believes competition only intensifies throughout the year. Jensen raised his price target for 3D to $11 from $10.50 but reiterates an Underweight rating on the shares.
05/23/17
PIPR
05/23/17
NO CHANGE
Target $14
PIPR
Underweight
3D Systems unlikely to post organic system growth this year, says Piper Jaffray
Piper Jaffray analyst Troy Jensen says he continues to believe that HP's (HPQ) expanded launch of the Jet Fusion 3D Printer will be a competitive headwind to 3D Systems' (DDD) SLS system sales in the second half of 2017. HP will help prevent 3D Systems from delivering organic system growth this year, Jensen tells investors in a research note. He raised his price target for 3D shares to $14 from $11 citing multiple expansion in the sector but reiterates an Underweight rating on the name.
03/09/17
SBSH
03/09/17
NO CHANGE
Target $19.5
SBSH
Neutral
Stratasys likely to sell off on the 'weak' guidance, says Citi
Citi analyst Kenneth Wong expects shares of Stratasys (SYYS), along with peer 3D Systems (DDD), to move lower following the company's "weak" guidance for 2017. The analyst adds, though, that Stratasys' new management may have baked in some conservatism into the outlook. He keeps a Neutral rating on the shares following the company's Q4 results.
AZN AstraZeneca
$34.08

0.13 (0.38%)

05/15/17
LEER
05/15/17
NO CHANGE
LEER
GlaxoSmithKline possible move to buyout Novartis stake makes sense, says Leerink
Leerink analyst Seamus Fernandez is not surprised by the news that GlaxoSmithKline (GSK) may buyout Novartis' (NVS) 36.5% stake in its Consumer Healthcare joint venture through a GBP8B deal sooner rather than later. The analyst believes this buyout could be beneficial as the infusion of additional cash from the buyout could bolster Novartis appetite for large scale M&A, including companies such as AstraZeneca (AZN) whose immune-oncology assets could complement its small-molecule focused oncology portfolio, according to the London Times.
05/12/17
05/12/17
UPGRADE

Neutral
AstraZeneca upgraded to Neutral at Credit Suisse
As previously reported, Credit Suisse analyst Rebekah Harper upgraded AstraZeneca to Neutral from Underperform after the company reported surprise positive headline results from the Phase 3 PACIFIC trial for Imfinzi in stage 3 unresectable lung cancer in all-comers, with positive progression free survival data. The analyst believes that AstraZeneca is in a "unique position" with this indication, with a likely two to three years lead versus competitors, as other P3s are not due until 2020+. Harper expects U.S. approval for AstraZeneca in this indication before the end of 2017.
05/17/17
JPMS
05/17/17
UPGRADE
Target $72
JPMS
Overweight
Clovis upgraded to Overweight from Neutral at JPMorgan
JPMorgan analyst Cory Kasimov upgraded Clovis Oncology (CLVS) to Overweight and raised his price target for the shares to $72 from $58. The stock closed yesterday up 2%, or $1.05, to $49.56. The shares are down 35% over the last two months for "no clear fundamental reason," Kasimov tells investors in a research note. The analyst is "increasingly comfortable" recommending Clovis ahead of its Phase 3 study evaluating Rubraca in maintenance ovarian cancer now that more PARP class data has emerged. He has not seen "convincing evidence" that there is a clear efficacy difference between Clovis' rucaparib, Tesaro's (TSRO) niraparib and AstraZeneca's (AZN) olaparib.
05/16/17
LEER
05/16/17
NO CHANGE
Target $36
LEER
Outperform
AstraZeneca price target raised to $36 from $33 at Leerink
Leerink analyst Seamus Fernandez raised his price target for AstraZeneca to $36 after hosting a call with a lung cancer specialist. The specialist believes that once approved, the uptake of AstraZeneca's Imfinzi in Stage III unresectable non-small cell lung cancer will be "significant" given the poor outcomes and general lack of an effective treatment standard in this setting, Fernandez tells investors in a research note. The analyst raised his peak worldwide forecasts for the drug by $1B and keeps an Outperform rating on AstraZeneca.
MNK Mallinckrodt
$39.86

-0.18 (-0.45%)

02/22/17
UBSW
02/22/17
NO CHANGE
Target $77
UBSW
Buy
UBS says FDA suspension for generic Concerta review a positive for Mallinckrodt
UBS analyst Marc Goodman noted the FDA agreed to suspend the deadline for submitting documentation in support of a hearing on the FDA's proposal to withdraw Mallinckrodt's ANDA for its generic Concerta. The entire process could take until the end of 2017, if not longer, said Goodman, who was only modeling one quarter of sales for generic Concerta, leaving potential for some upside, he tells investors. Goodman believes the delay is a modest positive for the stock and he reiterated his Buy rating and $77 price target on Mallinckrodt shares.
03/13/17
JEFF
03/13/17
NO CHANGE
Target $70
JEFF
Buy
Mallinckrodt price target lowered to $70 from $95 at Jefferies
Jefferies analyst Anthony Petrone lowered his price target for Mallinckrodt to $70 after updating his estimates. 2017 is a transitional year for the company, but "clearer skies" are ahead, Petrone tells investors in a research note. Acthar growth is supported by the data build out and volume gains, while Mallinckrodt's pipeline is being underappreciated, Petrone tells investors in a research note. The analyst notes that healthcare policy change will be gradual. He keep a Buy rating on Mallinckrodt.
03/31/17
PIPR
03/31/17
NO CHANGE
Target $83
PIPR
Overweight
Piper stays bullish on Mallinckrodt after management meetings
After traveling with management, Piper Jaffray analyst David Amsellem says he's staying bullish on Mallinckrodt. Management appears to be exploring all capital deployment options with the goal of driving multiple expansion, Amsellem tells investors in a research note. The company remains focused on further diversifying away from Acthar, he adds. Amsellem believes going private "should at least be explored." The analyst has an Overweight rating on Mallinckrodt with an $83 price target.
GSK GlaxoSmithKline
$42.96

-0.34 (-0.79%)

03/29/17
PIPR
03/29/17
NO CHANGE
Target $42
PIPR
Overweight
Mylan news a positive for Theravance, says Piper Jaffray
Piper Jaffray analyst Joshua Schimmer says Mylan's (MYL) complete response letter for its generic version of GlaxoSmithKline's Advair "buys time and will likely preserve some pricing power in the broader respiratory space." This will be important for GSK's commercialization of the closed triple following potential regulatory approval at year end, Schimmer tells investors in a research note. This is also positive for Theravance Biopharma (TBPH), which stands to receive a "meaningful" mid/high single digit royalty on the closed triple, the analyst contends. He reiterates an Overweight rating on Theravance with a $42 price target. The stock is up 49c to $36.47 in afternoon trading.
04/05/17
04/05/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Staples (SPLS) upgraded to Buy from Neutral at Citi with analyst Kate McShane saying her sum-of-the-parts analysis indicates the company should be worth closer to $7.9B versus the current market capitalization of $5.6B. This implies 30% upside for the shares, McShane tells investors in a research note after the Wall Street Journal reported Staples is exploring a possible sale. The analyst believes the exploration makes sense. She upped her price target for Staples to $12 from $9.50. 2. Wells Fargo (WFC) and Citi (C) upgraded to Outperform from Market Perform at Keefe Bruyette. 3. McCormick (MKC) upgraded to Neutral from Underweight at JPMorgan with analyst Ken Goldman saying he continues to view the stock as overvalued but notes management "sounded highly confident about current fundamentals." 4. Wynn Resorts (WYNN) upgraded to Buy from Hold at Argus with analyst John Staszak saying the company is benefiting from the "consistent improvement" of its Wynn Palace casino in Macau, along with the overall improvement of the Macau gambling market in general and the faster than expected rebound of the Macau VIP market in particular. 5. GlaxoSmithKline (GSK) upgraded to Neutral from Underperform at Exane BNP Paribas. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/05/17
EXAN
04/05/17
UPGRADE
EXAN
Neutral
GlaxoSmithKline upgraded to Neutral from Underperform at Exane BNP Paribas
FGEN FibroGen
$26.90

0.3 (1.13%)

01/18/17
RBCM
01/18/17
NO CHANGE
RBCM
FibroGen data positive, says RBC Capital
RBC Capital analyst Michael Yee says that data on Fibro-Gen's ASCO-GI for pancreatic cancer "looks positive." The analyst says that the drug "continues to show strong and promising activity in pancreatic cancer." He notes that 50% of the patients who finished the study became resection-eligible versus only 9% of patients in the control arm. Yee keeps an Outperform rating on the shares.
01/18/17
FBCO
01/18/17
NO CHANGE
Target $44
FBCO
Outperform
Credit Suisse views FibroGen data 'favorably'
Credit Suisse analyst Kennen MacKay notes that FibroGen's ASCO-GI abstracts were released with updated data from Pamrevlumab's Phase 2 neoadjuvant combo trial +/- standard of care gemcitabine/abraxane in non-resectable pancreatic cancer patients, and says initial OS data appears to suggest improved survival in the pamrevulab arm. The analyst views the update "favorably," though early, and awaits full presentation on Friday. He reiterates an Outperform rating and $44 price target on the shares.
NVS Novartis
$81.06

-0.23 (-0.28%)

04/18/17
WELS
04/18/17
NO CHANGE
WELS
Allergan partnership a 'promising free option,' says Wells Fargo
Wells Fargo analyst David Maris views Allergan's (AGN) partnership with Novartis (NVS) to conduct a Phase IIb study using its cenicriviroc and Novartis's lead FXR agonist for the treatment of nonalcoholic steatohepatitis as a "promising free option." The deal is a way to maximize Allergan's shots-on-goal in combination NASH treatments, Maris tells investors in a research note. He has an Outperform rating on Allergan shares.
04/05/17
04/05/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. AstraZeneca (AZN) downgraded to Neutral from Buy at UBS. 2. Novartis (NVS) downgraded to Market Perform from Outperform at Cowen with analyst Steve Scala saying he believes the company's earnings growth looks below the industry average given the current weakness in Alcon and Entresto's slow rollout. 3. MSG Networks (MSGN) downgraded to Neutral following NY Post report at Macquarie with analyst Tim Nollen citing valuation and maintained its $26 price target. 4. Generac (GNRC) downgraded to Sector Weight from Overweight at KeyBanc with analyst Jeffrey Hammond citing concerns that increased pricing incentives and normalizing storm activity are impacting the growth for the company's Residential home standby business. 5. Amgen (AMGN) downgraded to Hold from Buy at Jefferies with analyst Eun Yang saying she believes upside in the stock will likely be "muted" after her payor poll indicated continuing reimbursement challenges for Repatha, Amgen's PCSK9 inhibitor to treat high cholesterol. Yang also sees a "scarcity of blockbuster potential pipeline products" and feels a transformative acquisition is unlikely. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/21/17
ROTH
04/21/17
NO CHANGE
Target $12
ROTH
Buy
Conatus price target raised to $12 from $4 at Roth Capital
Roth Capital analyst Sa'ar Yaniv raised his price target for Conatus (CNAT) to $12 from $4 following discussions with management, 2016 results, assessment of the competitive cirrhosis space, and clarity from the Novartis (NVS) deal. The analyst believes Conatus' shares are undervalued and reiterates a Buy rating on the stock.
PRXL Parexel
$79.64

0.33 (0.42%)

05/23/17
05/23/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. McKesson (MCK) upgraded to Overweight from Neutral at JPMorgan with analyst Lisa Gill saying she believes additional value should be unlocked from the Change transaction and that the valuation discount versus peers is unwarranted. 2. Aegion (AEGN) upgraded to Buy from Hold at Craig-Hallum with analyst Eric Stine saying the recent pullback provides an attractive opportunity to own a "high-quality company" with positive trends across much of its business. 3. Wingstop (WING) upgraded to Conviction Buy from Buy at Goldman Sachs with analyst Karen Holthouse saying there is upside to her $36 price target. Holthouse believes Wingstop is well positioned for digital ordering and off-premise tailwinds and expects an acceleration in same-store-sales driven by national advertising momentum. 4. Parexel (PRXL) upgraded to Neutral from Sell at Goldman Sachs with analyst Robert Jones citing reduced consensus expectations and industry consolidation. 5. On Deck Capital (ONDK) upgraded to Outperform from Market Perform at FBR Capital with analyst Bob Ramsey saying he believes the company's path to profitability creates "significant" upside for the shares over the next 12 months. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
05/23/17
GSCO
05/23/17
UPGRADE
Target $77
GSCO
Neutral
Parexel upgraded to Neutral from Sell at Goldman Sachs
Goldman analyst Robert Jones upgraded Parexel to Neutral and raised its price target to $77 from $63 to reflect reduced consensus expectations and industry consolidation. The analyst said two large-scale Clinical transactions announced over the past month reinforce his view of consolidation in the CRO space and reduced downside risk for Parexel.
05/16/17
LEHM
05/16/17
NO CHANGE
Target $87
LEHM
Overweight
Parexel price target raised to $87 from $74 at Barclays
Barclays analyst Jack Meehan raised his price target for Parexel to $87 after the Wall Street Journal on May 8 reported the company is exploring a sale and Starboard Value on May 11 disclosed a 5.7% stake. The analyst believes Parexel's investment thesis has merits on a standalone basis and notes his new price target reflects a push for better operational improvement. With the potential for strategic alternatives to drive further upside, Meehan raised his upside case for the shares to $100. He keeps an Overweight rating on Parexel.
05/15/17
EVER
05/15/17
UPGRADE
EVER
Outperform
Parexel upgraded to Outperform from In Line at Evercore ISI
NSPR InspireMD
$0.57

0.0085 (1.53%)

MYL Mylan
$39.59

0.95 (2.46%)

05/10/17
WELS
05/10/17
NO CHANGE
Target $40
WELS
Market Perform
Mylan deals masking 'weak' organic sales, says Wells Fargo
Wells Fargo analyst David Maris believes Mylan's deals are masking the company's contracting organic growth. When excluding deals, Mylan's total third party sales declined approximately 4% in Q1, with North American Sales down 11%, Europe down 1% and Rest of World up 11%, Maris tells investors in a post-earnings research note. He believes Mylan this morning reported an essentially in-line quarter on earnings, but that organic sales were "weak," particularly in North America. Maris has a Market Perform rating on Mylan with a $40 price target.
05/22/17
LEHM
05/22/17
DOWNGRADE
Target $17
LEHM
Equal Weight
Momenta downgraded to Equal Weight from Overweight at Barclays
Barclays analyst Douglas Tsao downgraded Momenta Pharmaceuticals (MNTA) to Equal Weight citing the likelihood of generic manufacturers, most notably Mylan (MYL), winning approval for generic Copaxone in the coming months. The approvals could come before Momenta and its partner Sandoz win approval themselves for the 40mg dose, Tsao tells investors in a research note. He lowered his price target for the shares to $17 from $20.
05/01/17
BMOC
05/01/17
INITIATION
Target $50
BMOC
Outperform
Mylan initiated with an Outperform at BMO Capital
BMO Capital analyst GaryNachman started Mylan with an Outperform rating and $50 price target. The company is one of the best positioned to navigate through the challenging generic trends over the longer term, the analyst argues.
05/22/17
LEHM
05/22/17
UPGRADE
Target $50
LEHM
Overweight
Mylan upgraded to Overweight from Equal Weight at Barclays
Barclays analyst Douglas Tsao upgraded Mylan (MYL) to Overweight saying the chances of the company winning approval for its generic version of Copaxone this year are better than current market expectations. The approval come as soon as next month, Tsao tells investors in a research note. The analyst coupled the upgrade with a downgrade of Copaxone maker Momenta Pharmaceuticals to Equal Weight. The selloff in Mylan following the Q1 disclosure of deficiencies to Advair create a buying opportunity, the analyst contends. He raised his price target for the shares to $50 from $47. Mylan closed Friday down 21c to $37.94.
ABBV AbbVie
$65.84

0.4 (0.61%)

05/17/17
MAXM
05/17/17
NO CHANGE
Target $44
MAXM
Buy
Coherus could beat Humira competitors to market by 4 years, says Maxim
Maxim analyst Jason McCarthy said the invalidation of AbbVie's (ABBV) dosing patent for Humira is a "major victory" for Coherus Biosciences (CHRS) that has reduced its risk profile. The last IP hurdle to launching a Humira biosimilar is formulation, where Coherus has the advantage, said McCarthy, who believes the company could be first to market with a biosimilar by late 2018, which would be four years or more ahead of its competition. He raised his price target on Coherus shares to $44 from $43 and keeps a Buy rating on the stock, which is up $1.95, or 8.8%, to $24 in pre-market trading.
05/17/17
JEFF
05/17/17
NO CHANGE
Target $90
JEFF
Buy
AbbVie should sell off only 2% today on 'sentiment hit,' says Jefferies
Jefferies analyst Jeffrey Holford believes a "2% sentiment hit" to AbbVie shares is appropriate after the Patent Trial and Appeal Board invalidated the '135 dosing patent for Humira. The stock in premarket trading is down 3%, or $1.85, to $65.00. The analyst, however, does not see the '135 patent as a singular blocking patent against U.S. biosimilars and makes no changes to his estimates. He believes AbbVie's pipeline news flow through the second half of 2017 is being underappreciated and keeps a Buy rating on the shares with a $90 price target.
05/02/17
FBCO
05/02/17
NO CHANGE
Target $65
FBCO
Neutral
AbbVie price target raised to $65 from $60 at Credit Suisse
Credit Suisse analyst Vamil Divan raised his price target for AbbVie to $65 from $60 following Q1 results. The analyst reiterates a Neutral rating on the shares.
05/17/17
SBSH
05/17/17
NO CHANGE
Target $38
SBSH
Buy
Citi sees up to $8/share upside for Coherus on patent win
Citi analyst Mohit Bansal sees $4 to $8 per share upside for Coherus Biosciences (CHRS) after the Patent Trial and Appeal Board ruled in favor of the company's petitions for Inter Partes Review of AbbVie's (ABBV) '135 Patent. The stock in premarket trading is up 9%, or $1.95, to $24.00. The win makes a Humira biosimilar launch from Coherus more realistic, Bansal tells investors in a research note. Further, he believes the news makes an anti-TNF franchise partnership for Coherus with big bio-pharma more likely. He thinks a deal could be announced in the second half of 2017. Bansal keeps a Buy rating on Coherus with a $38 price target.
VRTX Vertex
$116.59

-2.35 (-1.98%)

04/17/17
LEER
04/17/17
NO CHANGE
Target $128
LEER
Outperform
Vertex price target raised to $128 from $115 at Leerink
Leerink analyst Geoffrey Porges raised his price target for Vertex to $128 from $115, citing multiple clinical catalysts that are still to read out in 2017 for TEZ/IVA and the next generation correctors VX-440 and VX-152. The analyst reiterates an Outperform rating on the shares.
05/01/17
ARGS
05/01/17
NO CHANGE
ARGS
Vertex price target raised to $145 from $115 at Argus
Argus analysts Katelyn Bayone and John Eade raised their price target on Vertex after the company reported higher than expected EPS. The analysts continue to believe that the outlook for the company's earnings is positive, given the outlook for its Orkambi drug. They raised their price target on the shares to $145 from $115 and keeps a Buy rating.
04/28/17
FBCO
04/28/17
NO CHANGE
Target $125
FBCO
Outperform
Vertex price target raised to $125 from $108 at Credit Suisse
Credit Suisse analyst Alethia Young raised her price target for Vertex to $125 from $108 and raised her probability of success to 75% from 50% to the triplet in the HetMin population. The analyst thinks it is likely that one of the assets of Vertex's four clinical next generation correctors will be the third piece of a regimen that can successfully treat the HetMin population. She reiterates an Outperform rating on the shares.
05/01/17
BARD
05/01/17
NO CHANGE
Target $136
BARD
Outperform
Vertex price target raised to $136 from $115 at Baird
Baird analyst Brian Skorney raised his price target on Vertex to $136 from $115 on the strength of CF revenues in Q1 and management's confidence in and commitment to developing a next generation combination to treat 80%-90% of CF patients. Skorney believes 2017 will be a transformational year for Vertex and reiterated his Outperform rating on the shares.
VCYT Veracyte
$8.25

-0.03 (-0.36%)

03/10/17
PIPR
03/10/17
NO CHANGE
PIPR
Piper says CMS restarts Local Coverage Determination process
Piper Jaffray analyst William Quirk said he believes the Centers for Medicare and Medicaid Services is now allowing Medicare Administrative Contractors to resume issuing Local Coverage Determinations, or LCDs. He points out that Myriad Genetics (MYGN) has two draft LCDs outstanding - a positive one expanding Prolaris coverage and a negative one rescinding Vectra DA coverage - and Veracyte (VCYT) has one draft LCD outstanding by Noridian for Percepta.
02/17/17
CANT
02/17/17
NO CHANGE
CANT
Overweight
Draft BCBS policy a positive for Veracyte, says Cantor
Cantor Fitzgerald analyst Bryan Brokmeier said a draft of a revised policy from BlueCross BlueShield of Tennessee proposes that Veracyte's (VCYT) Afirma be deemed medically necessary, while competing products, including one from Interpace Diagnostics (IDXG), are considered investigational. The draft policy is a positive that represents a $3.6M annual revenue opportunity to Veracyte given the systems' 3.3M covered lives, said Brokmeier, who keeps an Overweight rating on the shares.
02/27/17
02/27/17
NO CHANGE

Piper sees CMS halt of LCDs as net-positive for Myriad
As previously reported, Piper Jaffray analyst William Quirk noted that an industry blog uncovered that the Centers for Medicare and Medicaid Services has instructed all Medicare Administrative Contractors to not post new or revised Local Coverage Determinations, or LCDs, until further notice. He points out that Myriad Genetics (MYGN) has two draft LCDs outstanding - a positive one expanding Prolaris coverage and a negative one rescinding Vectra DA coverage. He sees the LCDs at risk for a temporary delay, which he views as net-positive for Myriad. In his re-issued note to investors, Quirk pointed out that a prior version mistakenly said Veracyte's (VCYT) Percepta LCD was a draft, noting in correction that the LCD was finalized in early February.
RMD ResMed
$69.60

0.09 (0.13%)

04/20/17
JPMS
04/20/17
DOWNGRADE
Target $71
JPMS
Neutral
ResMed downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst David Low downgraded ResMed to Neutral ahead of next week's Q3 results. Manufacturing challenges are likely to limit mask sales growth for the quarter despite the release of the new AirFit range, Low tells investors in a pre-earnings research note. He lowered his price target for the shares to $71 from $72.
02/01/17
NORL
02/01/17
NO CHANGE
NORL
Underperform
CMS pilot bundling rules would compress margins for ResMed, says Northland
Northland analyst Suraj Kalia noted that CMS introduced pilot bundling rules expected to begin in 2019, adding that bundling will compress margins significantly for ResMed and others in the durable medical equipment space. However, if Tom Price is confirmed as HHS head the industry will look to him for legislative relief, added Kalia. The firm keeps an Underperform rating on ResMed shares.
04/28/17
SBSH
04/28/17
DOWNGRADE
SBSH
Neutral
ResMed downgraded to Neutral from Buy at Citi
02/08/17
PIPR
02/08/17
NO CHANGE
PIPR
Piper says CMS delay of round 2019 a positive for ResMed, Inogen
Piper Jaffray analyst Matt O'Brien notes the Centers for Medicare & Medicaid Services announced last night the temporary delay of the round 2019 competitive durable medical equipment bidding process. The analyst views the news as a net positive for ResMed (RMD) and Inogen (INGN). The move could mark the bottom in reimbursement rates for oxygen therapy and CPAP, a positive for the durable medical equipment sector, O'Brien tells investors in a research note.
MASI Masimo
$85.83

-0.1 (-0.12%)

05/05/17
ROTH
05/05/17
NO CHANGE
Target $99
ROTH
Buy
Masimo price target lowered to $99 from $104 at Roth Capital
Roth Capital analyst Chris Lewis lowered his price target for Masimo to $99 from $104 noting that the stock was down despite "solid results," and saying he sees the reaction as possibly a "healthy reset" given the stock's run and heightened valuation. The analyst reiterates a Buy rating on the shares.
03/16/17
PIPR
03/16/17
DOWNGRADE
PIPR
Neutral
Masimo downgraded to Neutral from Overweight at Piper Jaffray
Piper Jaffray analyst William Quirk downgraded Masimo to Neutral citing valuation with the shares up 146% since the company announced a new CEO compensation package at the beginning of 2016 incentivizing a sale of the company. The analyst believes takeout expectations are justified, but his valuation models suggest limited upside from here. He keeps an $80 price target for the shares.
03/21/17
ROTH
03/21/17
NO CHANGE
Target $104
ROTH
Buy
Masimo price target raised to $104 from $88 at Roth Capital
Roth Capital analyst Chris Lewis raised his price target for Masimo (MASI) to $104 from $88 after hosting a fireside discussion with the company's CEO and Chairman Joe Kiani, and EVP and CFO Mark de Raad. The analyst has a reaffirmed bullish outlook on Masimo, supported by the Philips (PHG) strategic partnership, elevated Core SET growth outlook, new parameter market opportunities, and his expectation for a continued focus on driving "strong earnings growth." He reiterates a Buy rating on Masimo's shares.
04/04/17
WEDB
04/04/17
NO CHANGE
WEDB
Masimo price target raised to $100 from $95 at Wedbush
Wedbush analyst Tao Levy raised the estimates on Masimo citing the significant increase in the intensity of this year's flu season versus last year's. The analyst raised the price target on the shares to $100 from $95 and keeps an Outperform rating on the stock.
REGN Regeneron
$461.37

0.38 (0.08%)

05/05/17
LEER
05/05/17
NO CHANGE
Target $493
LEER
Outperform
Regeneron price target raised to $493 from $448 at Leerink
Leerink analyst Geoffrey Porges raised his price target for Regeneron to $493 from $448 following quarterly results, and given the strength of peer company multiples and greater conviction about long-term profitability. The analyst reiterates an Outperform rating on the shares.
05/05/17
ADAM
05/05/17
UPGRADE
Target $484
ADAM
Buy
Regeneron upgraded to Buy at Canaccord
As reported previously, Canaccord analyst John Newman upgraded Regeneron to Buy from Hold. The analyst cited the strong investor sentiment toward the Dupixent launch, which he believes will drive the shares higher into Q2 and Q3 earnings. He also believes there will be less focus on Eylea revenues, despite slowing growth. Newman raised his price target to $484 from $375 on Regeneron shares.
05/05/17
UBSW
05/05/17
NO CHANGE
Target $489
UBSW
Buy
Regeneron price target raised to $489 from $446 at UBS
UBS analyst Carter Gould raised his price target on Regeneron to $489 from $446 following Q1 results. The analyst lowered his Eylea U.S. sales estimates based on Q1 trends, but he saw positives in the Dupixent update, including strong demand in atopic dermatitis. Also, the company has seen positive proof-of-concept data in eosinophilic esophagitis, which he noted was not in Street models. Gould reiterated his Buy rating on Regeneron shares.
05/23/17
JEFF
05/23/17
NO CHANGE
Target $418
JEFF
Hold
Regeneron approval expected, but positive, says Jefferies
Jefferies analyst Biren Amin says that while the FDA approval of Regeneron's (REGN) Kevzara for the treatment of adult patients with moderate to severe active rheumatoid arthritis was expected, it is a positive. The label is in line with expectations and includes a risk of serious infections similar to Humira's (HUM) label, Amin tells investors in a research note. He notes that Regeneron disclosed a $39,000 wholesale acquisition cost for Kevzara, which is 30% lower than TNF competitors. The analyst has a Hold rating on Regeneron with a $418 price target.
INSM Insmed
$17.24

-0.13 (-0.75%)

06/09/16
PIPR
06/09/16
NO CHANGE
Target $24
PIPR
Overweight
Insmed withdrawal in Europe does little to change outlook, says Piper Jaffray
Piper Jaffray analyst Joshua Schimmer says Insmed's decision to withdraw its Marketing Authorization Application from the European Medicines Agency for Arikayce for the treatment of nontuberculous mycobacteria lung disease does little to change the company's outlook. Like the FDA, the European regulators want to see the results of the full Phase 3 Convert study, which will report in 2017, Schimmer tells investors in a research note. Success in the Phase 3 trial likely would have been needed to stay on the market anyways, the analyst contends. He keeps an Overweight rating on Insmed with a $24 price target.
05/04/17
LEER
05/04/17
NO CHANGE
Target $27
LEER
Outperform
Insmed price target raised to $27 from $21 at Leerink
Leerink analyst Joseph Schwartz raised his price target for Insmed to $27 from $21 to reflect Q1 net income/EPS and management's current estimates for the refractory NTM opportunity. The analyst notes that the upcoming Phase 3 data from the CONVERT study investigating Arikayce in patients with nontuberculous mycobacterium lung infections remains a key binary catalyst for investors. Additionally, he sees a positive outcome surrounding INS-1007 bolstering Insmed's position as a leading biotechnology company in the rare pulmonology disease space. The analyst reiterates an Outperform rating on the shares.
06/09/16
LEER
06/09/16
NO CHANGE
Target $21
LEER
Outperform
Insmed withdrawal in Europe a minor setback, says Leerink
Leerink analyst Joseph Schwartz says Insmed decided to withdraw its Marketing Authorization Application from the European Medicines Agency for its Arikayce in treating patients with nontuberculous mycobacterium infections. The analyst sees this setback as minor as Phase 3 CONVERT study continues to enroll patients allowing the company to return with "better, more convincing" clinical data at a later date. Schwartz reiterates an Outperform rating on the stock but lowered his price target on the shares to $21 from $23.
05/01/17
STFL
05/01/17
NO CHANGE
STFL
Insmed should be bought ahead of data, says Stifel
After speaking with three key opinion leaders familiar with Insmed's Arikayce drug, Stifel analyst Adam Walsh says all three experts think that the drug can meet its primary Phase III endpoint. The experts think that the drug's response rate could be about 30% higher than the standard of care. The analyst believes that this implies that the experts expect the Phase 3 results to be strong, and he recommends buying the stock ahead of the results which are due out in September. The analyst raised his price target on the stock to $27 from $23 and keeps a Buy rating on the shares.
BAYRY Bayer
$131.91

0.62 (0.47%)

04/06/17
JPMS
04/06/17
NO CHANGE
Target $128
JPMS
Overweight
Monsanto shares offer 'excellent' risk/reward proposition, says JPMorgan
JPMorgan analyst Jeffrey Zekauskas says shares of Monsanto (MON) at current levels offer an "excellent" risk/reward proposition. The analyst views capital appreciation potential to the end of 2017 as 11% or a 15% annual return. He sees downside risk of only 3%, to $112 per share, in the event that Bayer (BAYRY) is not able to consummate the acquisition. Zekauskas has increased confidence in the deal closing following recent regulatory rulings and keeps an Overweight rating on the name with a $128 price target.
01/06/17
JPMS
01/06/17
NO CHANGE
Target $128
JPMS
Overweight
Monsanto shares are mispriced, says JPMorgan
JPMorgan analyst Jeffrey Zekauskas says Monsanto (MON) shares are mispriced and offer an attractive risk/reward proposition. A first catalyst for the shares would be regulatory agreement in the Dow Chemical (DOW)/DuPont (DD) transaction, Zekauskas tells investors in a research note. The analyst thinks a favorable resolution to the Dow/DuPont merger would be seen as improving the probability of the success of the Bayer/Monsanto transaction. He notes that Bayer has agreed to purchase Monsanto for $128 per share in cash, which represents 21% appreciation potential should the deal close by year-end. Zekauskas thinks a "reasonable floor" price for Monsanto shares, should the deal fail, is $102. He keeps an Overweight rating on the name with a $128 price target.
03/03/17
JPMS
03/03/17
NO CHANGE
Target $128
JPMS
Overweight
EU approvals of other ag deals may narrow Monsanto deal spread, says JPMorgan
JPMorgan analyst Jeffrey Zekauskas said commentary from the CEOs of DuPont (DD) and Syngenta (SYT) and press reports from Europe suggest that their deals with Dow Chemical (DOW) and ChemChina, respectively, are likely to be approved. Approvals from Europe for those deals may "trigger a meaningful closing of the arbitrage spread" in Monsanto (MON) shares versus Bayer's (BAYRY) offer price, Zekauskas tells investors. He recommends buying Monsanto shares at current levels for this reason, adding that he believes the shares would only fall about 2.5%, or down to $112, in the event of the Bayer deal falling through. Zekauskas keeps an Overweight rating and $128 price target on Monsanto shares, which closed yesterday at just below $115 per share.
04/10/17
PIPR
04/10/17
NO CHANGE
Target $17
PIPR
Overweight
OncoMed price target lowered to $17 from $26 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff lowered his price target for OncoMed (OMED) to $17 from $26 following two negative announcements, namely that the Phase II YOSEMITE study of demcizumab in first line pancreatic cancer failed and Bayer (BAYRY) returned rights for ipafricept and vantictumab. The analyst also notes that now partner Celgene (CELG) will review all data on demcizumab including Phase II DENALI non-small cell lung cancer data and Phase Ib combo data with KEYTRUDA, although he does not expect Celgene to exercise its option. Tenthoff reiterates an Overweight rating on OncoMed's shares.

TODAY'S FREE FLY STORIES

WFC

Wells Fargo

$54.17

-0.71 (-1.29%)

10:14
07/22/17
07/22
10:14
07/22/17
10:14
Periodicals
Wells Fargo investigating information sent to attorney, Bloomberg reports »

Wells Fargo said it is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Oct

  • 15

    Jan

COKE

Coca-Cola Bottling

$240.86

-0.94 (-0.39%)

09:51
07/22/17
07/22
09:51
07/22/17
09:51
Hot Stocks
Coca-Cola Bottling announces 25c dividend for third quarter »

Coca-Cola Bottling…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PG

Procter & Gamble

$88.61

0.01 (0.01%)

09:41
07/22/17
07/22
09:41
07/22/17
09:41
Periodicals
Procter & Gamble finds itself 'besieged again,' Barron's says »

In a follow-up story,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Aug

PG

Procter & Gamble

$88.61

0.01 (0.01%)

09:40
07/22/17
07/22
09:40
07/22/17
09:40
Periodicals
Procter & Gamble finds itself 'besieged again,' Barron's says »

In a follow-up story,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Aug

DF

Dean Foods

$15.35

-0.02 (-0.13%)

09:33
07/22/17
07/22
09:33
07/22/17
09:33
Periodicals
Cheddar prices could rise further, Barron's says »

Prices for block cheddar…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Aug

KR

Kroger

, FDX

FedEx

$212.51

0.63 (0.30%)

09:25
07/22/17
07/22
09:25
07/22/17
09:25
Periodicals
Issuing debt to fund pensions 'not cause for worry,' Barron's says »

Issuing debt to fund…

KR

Kroger

FDX

FedEx

$212.51

0.63 (0.30%)

DAL

Delta Air Lines

$52.26

-0.57 (-1.08%)

DD

DuPont

$84.54

-0.29 (-0.34%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

SRPT

Sarepta

$43.41

2.48 (6.06%)

09:14
07/22/17
07/22
09:14
07/22/17
09:14
Periodicals
Upbeat sales news, guidance boost lift Sarepta shares, Barron's reports »

Sarepta's shares…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$1,025.67

-3.03 (-0.29%)

, SHLD

Sears

$8.83

-0.77 (-8.02%)

09:09
07/22/17
07/22
09:09
07/22/17
09:09
Periodicals
Nothing is 'Amazon-proof,' Barron's says »

Amazon's (AMZN) deal…

AMZN

Amazon.com

$1,025.67

-3.03 (-0.29%)

SHLD

Sears

$8.83

-0.77 (-8.02%)

HD

Home Depot

$146.65

-0.38 (-0.26%)

LOW

Lowe's

$73.84

1.28 (1.76%)

BBY

Best Buy

$54.14

0.18 (0.33%)

M

Macy's

$23.36

0.29 (1.26%)

KSS

Kohl's

$40.46

0.47 (1.18%)

ORLY

O'Reilly Automotive

$188.19

-0.5 (-0.26%)

AAP

Advance Auto Parts

$105.27

2.04 (1.98%)

WFM

Whole Foods

$41.71

-0.05 (-0.12%)

KR

Kroger

COST

Costco

$150.44

-0.55 (-0.36%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

  • 27

    Jul

  • 15

    Aug

  • 23

    Aug

  • 29

    Aug

BA

Boeing

$212.14

1.86 (0.88%)

, LMT

Lockheed Martin

$289.12

-0.55 (-0.19%)

08:58
07/22/17
07/22
08:58
07/22/17
08:58
Periodicals
Aviation, defense stocks have 'juicy yields,' Barron's says »

Some aerospace and…

BA

Boeing

$212.14

1.86 (0.88%)

LMT

Lockheed Martin

$289.12

-0.55 (-0.19%)

UTX

United Technologies

$123.49

1.04 (0.85%)

RTN

Raytheon

$169.37

0.59 (0.35%)

LLL

L3 Technologies

$176.62

-1.1 (-0.62%)

GD

General Dynamics

$204.55

2.15 (1.06%)

NOC

Northrop Grumman

$265.30

0.53 (0.20%)

COL

Rockwell Collins

$109.31

-0.04 (-0.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 26

    Jul

  • 26

    Jul

  • 26

    Jul

  • 27

    Jul

  • 27

    Jul

  • 28

    Jul

  • 15

    Aug

  • 23

    Aug

AMZN

Amazon.com

$1,025.67

-3.03 (-0.29%)

, GOOGL

Alphabet Class A

$993.84

1.65 (0.17%)

08:50
07/22/17
07/22
08:50
07/22/17
08:50
Periodicals
Amazon, others could be threat to fiberoptic markers, Barron's says »

Amazon.com (AMZN),…

AMZN

Amazon.com

$1,025.67

-3.03 (-0.29%)

GOOGL

Alphabet Class A

$993.84

1.65 (0.17%)

GOOG

Alphabet

$972.92

4.77 (0.49%)

AAPL

Apple

$150.27

-0.07 (-0.05%)

FB

Facebook

$164.43

-0.1 (-0.06%)

AAOI

Applied Optoelectronics

$89.95

1.15 (1.30%)

LITE

Lumentum

$63.35

2.9 (4.80%)

OCLR

Oclaro

$9.90

0.04 (0.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 26

    Jul

  • 27

    Jul

  • 01

    Aug

  • 02

    Aug

  • 03

    Aug

  • 05

    Sep

  • 13

    Sep

  • 13

    Sep

NKE

Nike

$59.95

0.85 (1.44%)

, FB

Facebook

$164.43

-0.1 (-0.06%)

08:28
07/22/17
07/22
08:28
07/22/17
08:28
Periodicals
AllianceBernstein's Caruso sees EPS as 'poor' report card, Barron's says »

Frank Caruso, the chief…

NKE

Nike

$59.95

0.85 (1.44%)

FB

Facebook

$164.43

-0.1 (-0.06%)

ISRG

Intuitive Surgical

$927.47

-44.26 (-4.55%)

ANET

Arista Networks

$152.92

-3.88 (-2.47%)

AB

AllianceBernstein

$24.75

0.1 (0.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

  • 27

    Jul

  • 27

    Jul

  • 03

    Aug

  • 08

    Aug

  • 16

    Aug

  • 17

    Aug

  • 21

    Aug

  • 13

    Sep

FLEX

Flex

$16.74

-0.07 (-0.42%)

, AAPL

Apple

$150.27

-0.07 (-0.05%)

07:53
07/22/17
07/22
07:53
07/22/17
07:53
Periodicals
Flex could rise 25% in a year, Barron's says »

Flex (FLEX) is using…

FLEX

Flex

$16.74

-0.07 (-0.42%)

AAPL

Apple

$150.27

-0.07 (-0.05%)

LNVGY

Lenovo

$12.63

0.18 (1.45%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

  • 01

    Aug

LUK

Leucadia

$26.45

0.03 (0.11%)

07:46
07/22/17
07/22
07:46
07/22/17
07:46
Periodicals
Leucadia shareholders to 'finally' see reward, Barron's says »

Five years after Leucadia…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MS

Morgan Stanley

$46.59

0.08 (0.17%)

07:39
07/22/17
07/22
07:39
07/22/17
07:39
Periodicals
Morgan Stanley CEO would not kill off Dodd-Frank, Barron's reports »

Morgan Stanley CEO James…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MS

Morgan Stanley

$46.59

0.08 (0.17%)

, JPM

JPMorgan

$90.89

-0.31 (-0.34%)

07:34
07/22/17
07/22
07:34
07/22/17
07:34
Periodicals
Big bank profits could be lifted 30% by deregulation, Barron's says »

While a major overhaul is…

MS

Morgan Stanley

$46.59

0.08 (0.17%)

JPM

JPMorgan

$90.89

-0.31 (-0.34%)

GS

Goldman Sachs

$220.18

-2.12 (-0.95%)

C

Citi

$66.00

-0.36 (-0.54%)

STT

State Street

$90.99

0.12 (0.13%)

BK

BNY Mellon

$53.36

-0.55 (-1.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 26

    Jul

  • 26

    Jul

  • 27

    Jul

  • 01

    Aug

  • 01

    Aug

  • 12

    Oct

  • 17

    Oct

  • 13

    Apr

  • 14

    Jul

  • 12

    Oct

BCC

Boise Cascade

$29.35

0.4 (1.38%)

, CAT

Caterpillar

$106.59

-0.73 (-0.68%)

07:19
07/22/17
07/22
07:19
07/22/17
07:19
Hot Stocks
Week in review: How Trump's policies moved stocks »

Catch up on the top…

BCC

Boise Cascade

$29.35

0.4 (1.38%)

CAT

Caterpillar

$106.59

-0.73 (-0.68%)

CPB

Campbell Soup

$52.00

0.08 (0.15%)

LVB

Steinway Musical

GLW

Corning

$31.85

0.14 (0.44%)

MRK

Merck

$62.63

-0.31 (-0.49%)

PFE

Pfizer

$33.48

-0.06 (-0.18%)

AMZN

Amazon.com

$1,025.67

-3.03 (-0.29%)

AET

Aetna

$156.31

0.58 (0.37%)

ANTM

Anthem

$190.65

-0.04 (-0.02%)

CNC

Centene

$84.73

-0.67 (-0.78%)

CI

Cigna

$174.23

-0.26 (-0.15%)

HNT

Health Net

HUM

Humana

$235.92

0.09 (0.04%)

MOH

Molina Healthcare

$71.15

-0.9 (-1.25%)

UNH

UnitedHealth

$191.78

0.28 (0.15%)

WCG

WellCare

$183.87

0.1 (0.05%)

X

U.S. Steel

$23.68

-0.47 (-1.95%)

STLD

Steel Dynamics

$37.51

-0.18 (-0.48%)

NUE

Nucor

$60.23

0.31 (0.52%)

CYH

Community Health

$9.27

0.01 (0.11%)

HCA

HCA Holdings

$85.73

-0.03 (-0.03%)

LPNT

LifePoint

$65.35

-0.15 (-0.23%)

THC

Tenet

$20.65

-0.02 (-0.10%)

UHS

Universal Health

$124.42

-0.58 (-0.46%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 25

    Jul

  • 25

    Jul

  • 26

    Jul

  • 26

    Jul

  • 26

    Jul

  • 26

    Jul

  • 27

    Jul

  • 27

    Jul

  • 28

    Jul

  • 30

    Jul

  • 01

    Aug

  • 01

    Aug

  • 02

    Aug

  • 02

    Aug

  • 02

    Aug

  • 02

    Aug

  • 03

    Aug

  • 03

    Aug

  • 04

    Aug

  • 04

    Aug

  • 08

    Aug

  • 14

    Aug

  • 23

    Aug

  • 27

    Aug

  • 22

    Sep

  • 26

    Sep

  • 27

    Sep

MET

MetLife

$54.65

0.07 (0.13%)

18:20
07/21/17
07/21
18:20
07/21/17
18:20
Periodicals
U.S. regulators to go over MetLife suit at July 28 meeting, Reuters says »

Leaders at the U.S.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Aug

  • 14

    Aug

  • 15

    Aug

OTEX

OpenText

$33.06

-0.02 (-0.06%)

, COVS

Covisint

18:11
07/21/17
07/21
18:11
07/21/17
18:11
Hot Stocks
OpenText says Covisint proposal shows 'compelling' overall value »

OpenText (OTEX) announced…

OTEX

OpenText

$33.06

-0.02 (-0.06%)

COVS

Covisint

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Aug

TOSBF

Toshiba, also use TOSYY

$2.47

0.1002 (4.23%)

, TOSYY

Toshiba, also use TOSBF

$14.90

0.8 (5.67%)

17:39
07/21/17
07/21
17:39
07/21/17
17:39
Periodicals
Toshiba sees bringing in about $360 in profit from Landis+Gyr IPO, Nikkei says »

Toshiba sees reaping…

TOSBF

Toshiba, also use TOSYY

$2.47

0.1002 (4.23%)

TOSYY

Toshiba, also use TOSBF

$14.90

0.8 (5.67%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MON

Monsanto

$117.38

0.37 (0.32%)

17:38
07/21/17
07/21
17:38
07/21/17
17:38
Periodicals
Breaking Periodicals news story on Monsanto »

Monsanto says some…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FSFG

First Savings Financial Group

$53.02

0.095 (0.18%)

17:34
07/21/17
07/21
17:34
07/21/17
17:34
Hot Stocks
First Savings Financial Group , First National Bank of Odon to merge »

First Savings Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NAUH

National American University

$2.36

-0.0236 (-0.99%)

17:26
07/21/17
07/21
17:26
07/21/17
17:26
Hot Stocks
National American University to acquire H-PU, terms not disclosed »

National American…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Aug

QEP

QEP Resources

$9.22

-0.27 (-2.85%)

17:25
07/21/17
07/21
17:25
07/21/17
17:25
Hot Stocks
QEP Resources names Mary Shafer-Malicki to board of directors »

According to a regulatory…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

CLSN

Celsion

$1.85

-0.07 (-3.65%)

17:18
07/21/17
07/21
17:18
07/21/17
17:18
Syndicate
Celsion files to sell 4.87M shares of common stock for holders »

Issuable upon exercise of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

REED

Reed's

16:54
07/21/17
07/21
16:54
07/21/17
16:54
Hot Stocks
Breaking Hot Stocks news story on Reed's »

Raptor/Harbor Reeds…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.